Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing
Posted:
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
Read the full article in the latest MedCity News blog post here.
Artificial Intelligence is no longer a future concept in healthcare — it is already reshaping how clinicians work, how patients are treated, and how health systems operate under pressure.
But while the excitement around AI continues to grow, the real…
For decades, hospitals were designed around buildings, departments, and paper-based processes.
But healthcare is changing rapidly.
Rising patient demand, workforce shortages, digital transformation, and the shift toward preventative and community-based care are forcing healthcare leaders to rethink what a hospital…
Attendees
Sponsors and Exhibitors
Contact us